Open AccessSynergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa
Author(s) -
Yulin Zhang,
Jun Zhao,
Jiajing Han,
Yanyan Fan,
Zhengping Xiong,
Xiaohui Zou,
Binbin Li,
Xinmeng Liu,
Ziyao Li,
Binghuai Lu,
Bin Cao
Publication year - 2022
Publication title -
microbiology spectrum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.502
H-Index - 51
ISSN - 2165-0497
DOI - 10.1128/spectrum.02740-21
Subject(s) - ceftazidime/avibactam , avibactam , microbiology and biotechnology , ceftazidime , pseudomonas aeruginosa , drug resistance , biology , antimicrobial , efflux , bacteria , genetics
Handling the infections by extensively drug-resistantPseudomonas aeruginosa (XDRPA) strains is challenging due to their complicated antibiotic resistance mechanisms in immunosuppressed patients with pulmonary diseases (e.g., cystic fibrosis, chronic obstructive pulmonary disease, and lung transplant), ventilator-associated pneumonia, and bloodstream infections. The current study suggested the potentiality of the ceftazidime-avibactam-imipenem combination against XDRPA withbla AmpC overexpression or mutation, decreased OprD porin, and/or upregulated efflux pumps.